The efficacy of mirtazapine in agitated patients with Alzheimer’s disease: A 12-week open-label pilot study
Sibel Cakir, Isin Baral KulaksizogluIstanbul University, Istanbul Medical School, Psychiatry Department, Geropsychiatry Unit, Istanbul, TurkeyAbstract: Agitation is one of the most devastating behavioral symptoms in demented patients but there is little evidence about effective and safe pharmacother...
Guardado en:
Autores principales: | Sibel Cakir, Isin Baral Kulaksizoglu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d22150e1f92b4c6193e074ebd0475a32 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Optimal nonpharmacological management of agitation in Alzheimer’s disease: challenges and solutions
por: Millán-Calenti JC, et al.
Publicado: (2016) -
Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder
por: Nagao K, et al.
Publicado: (2013) -
Severe agitation in severe early-onset Alzheimer’s disease resolves with ECT
por: Aksay SS, et al.
Publicado: (2014) -
An update on the toxicity of Aβ in Alzheimer’s disease
por: Jürgen Götz, et al.
Publicado: (2008) -
Update on the use of memantine in Alzheimer’s disease
por: Robert J van Marum
Publicado: (2009)